NCT00735007View on ClinicalTrials.gov

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

PHASE3CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

January 31, 2009

Conditions
Multiple Sclerosis
Interventions
DRUG

Rebif® New Formulation (RNF) using RebiSmartTM

RNF 44 mg, 3 times a week by subcutaneous injection.

Trial Locations (6)

02370

US Local Medical Information, Rockland

Unknown

Canada, Local Medical Information, Ontario, British Columbia, Quebec

Germany, Local Medical Information, Hamburg, Ulm, Berlin, Erbach

Italy, Local Medical Information, Chieti & Roma

Spain, Local Medical Information, Barcelona & Madrid

Sweden, Local Medical Information, Sweden

Sponsors

Lead Sponsor

EMD Serono
All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT00735007 - 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis. | Biotech Hunter | Biotech Hunter